|
|
By Maria-Teresa Gutierrez-Lugo, Ph.D., Office of Biotechnology Products, OPQ/CDER/FDA
Prior knowledge, platforms, parallel backup programs, and strategic timing all come into play when rapidly scaling up a mAbs development program in response to a public health emergency.
|